Innate Pharma hires Jennifer Butlers to lead commercialisation of leukaemia drug Lumoxiti
French company Innate Pharma have announced the appointment of Jennifer Butler to the position of Executive Vice President and General Manager.
The appointment, effective 11 March 2019, will see Butler lead Innate Pharma’s US corporate activities focusing on the establishment of the Company’s US operations in support of the commercialization of cancer drug, Lumoxiti.
Bringing to the role more than 20 years’ worth of strategic marketing and commercial leadership experience across several different therapeutic areas, Butler as led and built multiple global and US commercial teams, including the product launch of Imfinzi, while serving as the Global Commercial Head of Immuno-oncology at AstraZeneca.
“We welcome Jennifer to the Innate team. Her skills and leadership will be invaluable to Innate to support our expansion into the US and the execution of our goals for the commercialization of Lumoxiti,” Mondher Mahjoubi, Chief Executive Officer of Innate Pharma, said.
“Jennifer is an accomplished and successful commercial leader with deep expertise in immuno-oncology. She has an impressive track record of establishing commercial operations and successfully executing drug launches in the US. This is an exciting and rewarding year for Innate as we not only have the ability to discover and develop potential novel therapeutics in high unmet need patient populations, but are now able to provide the first FDA approved alternative treatment in 20 years to third line hairy cell leukaemia patients.”
Butler joins Innate from Singaporean firm Tessa Therapeutics, a clinical-stage oncology company, in which she served as Chief Business Officer, Chief Commercial Officer and Head of US operations, responsible for global business development and commercial strategy.
Prior to Tessa, Butler spent more than 10 years at Anglo Swedish multinational AstraZeneca. Butler has also worked as an analyst in Equity Capital Markets at Merrill Lynch.
“I am excited to be joining Innate Pharma at this important inflection point as it transitions from a R&D organization into a fully-integrated biotechnology company,” Jennifer Butler said of her own appointment.
“We are in a unique and privileged position for Innate to build an oncology commercial infrastructure for Lumoxiti that we will be able to leverage for the launch, subject to regulatory approval in the US, of our proprietary asset IPH4102. I look forward to leading a collaborative and seamless transition of commercial operations from AstraZeneca for Lumoxiti while building out Innate’s commercial and medical affairs organization. These efforts are the building blocks